Similar articles

• What is next in ALS clinical trials?

  Sorenson EJ. Sorenson EJ. Neurology. 2007 Aug 21;69(8):719-20. doi: 10.1212/01.wnl.0000271093.41793.ff. Neurology. 2007. PMID: 17709702 No abstract available.
• ALS issues in clinical trials. Missing data.

  Thompson JL, Levy G. Thompson JL, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:48-51. doi: 10.1080/17434470410019753. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512872 Review. No abstract available.
• Selecting promising ALS therapies in clinical trials.

  Cheung YK, Gordon PH, Levin B. Cheung YK, et al. Neurology. 2006 Nov 28;67(10):1748-51. doi: 10.1212/01.wnl.0000244464.73221.13. Neurology. 2006. PMID: 17130405 Review.
• Improving efficiency of ALS clinical trials using lead-in designs.

  Moore DH 2nd, Miller RG. Moore DH 2nd, et al. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004 Sep;5 Suppl 1:57-60. doi: 10.1080/17434470410019997. Amyotroph Lateral Scler Other Motor Neuron Disord. 2004. PMID: 15512875
• The biopharmaceutical industry and new drugs for amyotrophic lateral sclerosis.

  Malta E. Malta E. Adv Neurol. 1995;68:263-9; discussion 271-5. Adv Neurol. 1995. PMID: 8787239